May 07, 2014 9:20am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK), announced that it is expanding its global
presence with the establishment of a global supply chain operation in
Ireland. OPKO is recruiting employees immediately for a range of initial
positions, including material and vendor selection, quality assurance,
quality control, manufacturing, logistics and sales functions to support
the ongoing global launch of its 4Kscore™ diagnostic test and in
anticipation of the commercial launch of RAYALDEE ™. OPKO’s supply
chain operation in Ireland is also expected to manage the global supply
of other products over the next several years. The Irish operation will
also serve as a global holding company for many of OPKO’s non-U.S.
subsidiaries and as a platform for future strategic acquisitions.
“Ireland’s government and universities have a proven record of
commitment and robust partnerships with regard to education and training
for pharmaceutical manufacturing, quality assurance, quality control and
supply logistics. As we build our global supply chain and quality team,
we are excited to choose Ireland for its highly skilled and educated
workforce,” said Phillip Frost, M.D., Chairman and Chief Executive
Officer of OPKO.
About OPKO Health, Inc.
We are a multi-national biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large and rapidly
growing medical markets by leveraging our discovery, development and
commercialization expertise and our novel and proprietary technologies.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding expectations around our global
supply chain operations in Ireland, expectations around the launch and
commercialization of our products, including the 4Kscore and RAYALDEE,
whether the 4Kscore, RAYALDEE or any of our products in development will
be successfully commercialized, whether the Irish operations will
manage the global supply of our products and serve as a platform for
future strategic acquisitions, as well as other non-historical
statements about our expectations, beliefs or intentions regarding our
business, technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or results to
differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described in our
Annual Reports on Form 10-K filed and to be filed with the Securities
and Exchange Commission and in our other filings with the Securities and
Exchange Commission, as well as the risks inherent in funding,
developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments, that
earlier clinical results of effectiveness and safety may not be
reproducible or indicative of future results, that RAYALDEE, the
4Kscore, and/or any of our compounds or diagnostic products under
development may fail, may not achieve the expected results or
effectiveness and may not generate data that would support the approval
or marketing of products for the indications being studied or for other
indications, that currently available over-the-counter and prescription
products, as well as products under development by others, may prove to
be as or more effective than our products for the indications being
studied. In addition, forward-looking statements may also be adversely
affected by general market factors, competitive product development,
product availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
OPKO Health, Inc.
Steven D. Rubin or Adam Logal, 305-575-4100
Source: OPKO Health, Inc.
Released May 7, 2014
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page